Sulfur containing amino acids and human disease

Biomedicine and Pharmacotherapy

Volumn 58, Issue 1, 2004, Pages 47-55

  Townsend, Danyelle M ^a   Tew, Kenneth D ^a   Tapiero, Haim ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIV PARIS SUD   (France)

Author keywords

Cysteine; Methionine; One carbon metabolism; Sulfuration

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYSTEINE; METHIONINE; METHIONINE SYNTHASE; SULFUR AMINO ACID; THIOL DERIVATIVE;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMINO ACID TRANSPORT; CANCER; CARBON METABOLISM; CELL ACTIVITY; CYSTINURIA; DIETARY INTAKE; DNA POLYMORPHISM; DOWN SYNDROME; ENZYME DEFICIENCY; GENETIC DISORDER; HOMOCYSTINURIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAMMAL; NEURAL TUBE DEFECT; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; VASCULAR DISEASE;

EID: 1642524273     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.11.005     Document Type: Review

References (73)

1. Wagner C., Decha-Umphai W., Corbin J. Phosphorylation modulates the activity of glycine N-methyltransferase, a folate binding protein. In vitro phosphorylation is inhibited by the natural folate ligand. J Biol Chem. 264:(16):1989;9638-9642.
2. Jencks D.A., Mathews R.G. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. Effects of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. J Biol Chem. 262:(6):1987;2485-2493.
3. Wagner C., Briggs W.T., Cook R.J. Inhibition of glycine N-methyltransferase activity by folate derivatives: implications for regulation of methyl group metabolism. Biochem Biophys Res Commun. 127:(3):1985;746-752.
4. Kutzbach C., Stokstad E.L. Feedback inhibition of methylene- tetrahydrofolate reductase in rat liver by S-adenosylmethionine. Biochim Biophys Acta. 139:(1):1967;217-220.
5. Townsend D.M., Tew K.D., Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother. 57:(3-4):2003;145-155.
6. Choi S.W., Mason J.B. Folate and carcinogenesis: an integrated scheme. J Nutr. 130:(2):2000;129-132.
7. Mason J.B. Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr. 133:(Suppl 3):2003;941S-947S.
8. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 56:(1):1969;111-128.
9. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 324:(17):1991;1149-1155.
10. Kang S.S., Wong P.W.K., Malinow M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr. 12:1992;279-298.
11. Vollset S.E., Refsum H., Tverdal A., Nygard O., Nordrehaug J.E., Tell G.S., et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 74:(1):2001;130-136.
12. McKusick V.A. Heritable disorders of connective tissue. 3rd ed :1966;155 C.V. Mosby, St. Louis.
13. Ubbink J.B., Vermaak W.J., van der Merwe A., Becker P.J. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 57:(1):1993;47-53.
14. Jacques P.F., Selhub J., Bostom A.G., Wilson P.W., Rosenberg I.H. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 340:(19):1999;1449-1454.
15. Riddell L.J., Chisholm A., Williams S., Mann J.I. Dietary strategies for lowering homocysteine concentrations. Am J Clin Nutr. 71:(6):2000;1448-1454.
16. Carson N.A. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 37:1962;505-513.
17. Gerritsen T., Vaughn J.G., Waisman H.A. The identification of homocystine in the urine. Biochem Biophys Res Commun. 9:1962;493-496.
18. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 37:(1):1985;1-31.
19. Fowler B., Kraus J., Packman S., Rosenberg L.E. Homocystinuria. Evidence for three distinct classes of cystathionine beta-synthase mutants in cultured fibroblasts. J Clin Invest. 61:(3):1978;645-653.
20. Skovby F., Krassikoff N., Francke U. Assignment of the gene for cystathionine beta-synthase to human chromosome 21 in somatic cell hybrids. Hum Genet. 65:(3):1984;291-294.
21. Munke M., Kraus J.P., Ohura T., Francke U. The gene for cystathionine beta-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. Am J Hum Genet. 42:(4):1988;550-559.
22. Kraus J.P., Oliveriusova J., Sokolova J., Kraus E., Vlcek C., de Franchis R., et al. The human cystathionine beta-synthase (CBS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics. 52:(3):1998;312-324.
23. Kraus J.P., Janosik M., Kozich V., Mandell R., Shih V., Sperandeo M.P., et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat. 13:(5):1999;362-375.
24. Kraus J.P. Komrower lecture. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis. 17:(4):1994;383-390.
25. Abbott M.H., Folstein S.E., Abbey H., Pyeritz R.E. Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. Am J Med Genet. 26:(4):1987;959-969.
26. Frimpter G.W. Cystathioninuria: nature of the defect. Science. 149:(688):1965;1095-1096.
27. Wong L.T., Hardwick D.F., Applegarth D.A., Davidson A.G. Review of metabolic screening program of children's hospital, Vancouver, British Columbia. 1971-1977. Clin Biochem. 12:(5):1979;167-172.
28. Smith A.J., Strang L.B. An inborn error of metabolism with the urinary excretion of alpha-hydroxy-butyric acid and phenylpyruvic acid. Arch Dis Child. 33:1958;109-113.
29. Tapiero H., Tew K.D., Gaté L., Machover D. Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. Biomed Pharmacother. 55:2001;381-390.
30. Luhby A.L., Cooperman J.M., Pesci-Bourel A. A new inborn error of metabolism: folic acid responsive megaloblastic anemia, ataxia, mental retardation, and convulsions. J Pediat. 67:1965;1052. [Abstract].
31. Lanzkowsky P., Erlandson M.E., Bezan A.I. Isolated defect of folic acid absorption associated with mental retardation and cerebral calcification. Blood. 34:(4):1969;452-465.
32. Wollaston W.H. On cystic oxide, a new species of urinary calculus. Phil Trans Roy Soc Lond. 100:1810;223-230.
33. Calonge M.J., Gasparini P., Chillaron J., Chillon M., Gallucci M., Rousaud F., et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet. 6:(4):1994;420-425.
34. Lee W.S., Wells R.G., Sabbag R.V., Mohandas T.K., Hediger M.A. Cloning and chromosomal localization of a human kidney cDNA involved in cystine, dibasic, and neutral amino acid transport. J Clin Invest. 91:(5):1993;1959-1963.
35. Feliubadalo L., Font M., Purroy J., Rousaud F., Estivill X., Nunes V., et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo+AT) of rBAT. International Cystinuria Consortium. Nat Genet. 23:(1):1999;52-57.
36. Leclerc D., Wilson A., Dumas R., Gafuik C., Song D., Watkins D., et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA. 95:(6):1998;3059-3064.
37. Wilson A., Leclerc D., Rosenblatt D.S., Gravel R.A. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum Mol Genet. 8:(11):1999;2009-2016.
38. Wilson A., Platt R., Wu Q., Leclerc D., Christensen B., Yang H., et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Molec Genet Metab. 67:1999;317-323.
39. Hobbs C.A., Sherman S.L., Yi P., Hopkins S.E., Torfs C.P., Hine R.J., et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet. 67:(3):2000;623-630.
40. James S.J., Pogribna M., Pogribny I.P., Melnyk S., Hine R.J., Gibson J.B., et al. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr. 70:(4):1999;495-501.
41. Doolin M.T., Barbaux S., McDonnell M., Hoess K., Whitehead A.S., Mitchell L.E. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet. 71:(5):2002;1222-1226.
42. Gaughan D.J., Barbaux S., Kluijtmans L.A., Whitehead A.S. The human and mouse methylenetetrahydrofolate reductase (MTHFR) genes: genomic organization, mRNA structure and linkage to the CLCN6 gene. Gene. 257:(2):2000;279-289.
43. Sibani S., Christensen B., O'Ferrall E., Saadi I., Hiou-Tim F., Rosenblatt D.S., et al. Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat. 15:(3):2000;280-287.
44. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis. 19:(5):1996;589-594.
45. Goyette P., Sumner J.S., Milos R., Duncan A.M., Rosenblatt D.S., Matthews R.G., et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 7:(2):1994;195-200.
46. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:(1):1995;111-113.
47. Schneider J.A., Rees D.C., Liu Y.T., Clegg J.B. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 62:(5):1998;1258-1260.
48. McAndrew P.E., Brandt J.T., Pearl D.K., Prior T.W. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res. 83:(2):1996;195-198.
49. Bragley P.J., Selhub J. A common mutation in the methylene- tetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA. 95:1998;13217-13220.
50. Friso S., Choi S.W., Girelli D., Mason J.B., Dolnikowski G.G., Bagley P.J., et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA. 99:(8):2002;5606-5611.
51. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:(1):1996;7-9.
52. Kluijtmans L.A., van den Heuvel L.P., Boers G.H., Frosst P., Stevens E.M., van Oost B.A., et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 58:(1):1996;35-41.
53. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 288:(16):2002;2023-2031.
54. Christensen B., Arbour L., Tran P., Leclerc D., Sabbaghian N., Platt R., et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet. 84:(2):1999;151-157.
55. Ou C.Y., Stevenson R.E., Brown V.K., Schwartz C.E., Allen W.P., Khoury M.J., et al. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet. 63:(4):1996;610-614.
56. Mornet E., Muller F., Lenvoise-Furet A., Delezoide A.L., Col J.Y., Simon-Bouy B., et al. Screening of the C677T mutation on the methylenetetrahydrofolate reductase gene in French patients with neural tube defects. Hum Genet. 100:(5-6):1997;512-514.
57. Speer M.C., Worley G., Mackey J.F., Melvin E., Oakes W.J., George T.M. The thermolabile variant of methylenetetrahydrofolate reductase (MTHFR) is not a major risk factor for neural tube defect in American Caucasians. The NTD Collaborative Group. Neurogenetics. 1:(2):1997;149-150.
58. Motulsky A.G. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 58:(1):1996;17-20.
59. Pietrzyk J.J., Bik-Multanowski M., Sanak M., Twardowska M. Polymorphisms of the 5,10-methylenetetrahydrofolate and the methionine synthase reductase genes as independent risk factors for spina bifida. J Appl Genet. 44:(1):2003;111-113.
60. Pogribna M., Melnyk S., Pogribny I., Chango A., Yi P., James S.J. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet. 69:(1):2001;88-95.
61. O'Leary V.B., Parle-McDermott A., Molloy A.M., Kirke P.N., Johnson Z., Conley M., et al. MTRR and MTHFR polymorphism: link to Down syndrome? Am J Med Genet. 107:(2):2002;151-155.
62. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 17:(3):1985;278-282.
63. Religa D., Styczynska M., Peplonska B., Gabryelewicz T., Pfeffer A., Chodakowska M., et al. Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 16:(2):2003;64-70.
64. Hoffman R.M. Methionine dependence in cancer cells - a review. In Vitro. 18:(5):1982;421-428.
65. Hoffman R.M. Altered methionine metabolism and transmethylation in cancer. Anticancer Res. 5:(1):1985;1-30.
66. Liteplo R.G., Hipwell S.E., Rosenblatt D.S., Sillaots S., Lue-Shing H. Changes in cobalamin metabolism are associated with the altered methionine auxotrophy of highly growth autonomous human melanoma cells. J Cell Physiol. 149:(2):1991;332-338.
67. Tautt J.W., Anuszewska E.L., Koziorowska J.H. Methionine regulation of N-5-methyltetrahydrofolate: homocysteine methyltransferase and its influence on the growth and protein synthesis in normal, neoplastic, and transformed cells in culture. J Natl Cancer Inst. 69:(1):1982;9-14.
68. Fiskerstrand T., Christensen B., Tysnes O.B., Ueland P.M., Refsum H. Development and reversion of methionine dependence in a human glioma cell line: relation to homocysteine remethylation and cobalamin status. Cancer Res. 54:(18):1994;4899-4906.
69. Tang B., Li Y.N., Kruger W.D. Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. Cancer Res. 60:(19):2000;5543-5547.
70. Matsuo K., Hamajima N., Hirai T., Kato T., Inoue M., Takezaki T., et al. Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev. 3:(4):2002;353-359.
71. Paz M.F., Avila S., Fraga M.F., Pollan M., Capella G., Peinado M.A., et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 62:(15):2002;4519-4524.
72. Skibola C.F., Smith M.T., Kane E., Roman E., Rollinson S., Cartwright R.A., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA. 96:(22):1999;12810-12815.
73. Wiemels J.L., Smith R.N., Taylor G.M., Eden O.B., Alexander F.E., Greaves M.F. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA. 98:(7):2001;4004-4009.